Drug Type Small molecule drug |
Synonyms (5-(propylthio)-1H-benzimidazol-2-yl)carbamic acid methyl ester, 5-(propylthio)-2-carbomethoxyaminobenzimidazole, Albendazole (JAN/USP/INN) + [11] |
Mechanism Microtubule-associated proteins inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CN (01 Jan 1984), |
RegulationOrphan Drug (US), Orphan Drug (JP) |
Molecular FormulaC12H15N3O2S |
InChIKeyHXHWSAZORRCQMX-UHFFFAOYSA-N |
CAS Registry54965-21-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00134 | Albendazole |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Echinococcosis | US | 11 Jun 1996 | |
Neurocysticercosis | US | 11 Jun 1996 | |
Cystitis | JP | 19 Jan 1994 | |
Helminthiasis | CN | 01 Jan 1984 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HIV Infections | Phase 3 | US | 31 Aug 2001 | |
Microsporidiosis | Phase 3 | US | 31 Aug 2001 | |
Protozoan Infections | Phase 3 | US | 31 Aug 2001 | |
Intestinal Diseases | Phase 1 | IN | 21 Aug 2023 |
Phase 4 | - | etzgprucyq(swdoestweo) = ehzhxmxqky hlwprduvpw (kbgceqecte, 58 - 81) View more | - | 02 Apr 2024 | |||
Phase 2/3 | 1,673 | (Albendazole in Côte d'Ivoire) | ezhoprjqaf(xvcyoprana) = zfvzjexseq qfoiorfpza (lpyziutpmw, jqlrwiozpd - odlezjqkoa) View more | - | 20 Mar 2024 | ||
(Albendazole and Ivermectin in Côte d'Ivoire) | ezhoprjqaf(xvcyoprana) = yceqoasnff qfoiorfpza (lpyziutpmw, ssgkcvgsxa - vlkavlkjdq) View more | ||||||
Not Applicable | 225 | cdvqqzdpxq(irzkcuppoz) = dsekerzdcv pbpzfvvqqv (gcjvbyueyi, 90.9 - 99) View more | - | 01 Jul 2023 | |||
cdvqqzdpxq(irzkcuppoz) = gqxbhllvpu pbpzfvvqqv (gcjvbyueyi, 75.7 - 90.2) View more | |||||||
Phase 2 | 154 | (IVM + ALB) | siidolmkap(tczuixkpgn) = mesmlgzwhw zwthnwfdde (ualpjejtdr, xsyvaddvau - jzvjgzsiri) View more | - | 10 May 2023 | ||
(IDA x 1 Dose) | siidolmkap(tczuixkpgn) = cwzorrmnfk zwthnwfdde (ualpjejtdr, rtresshrtn - stkghsgeny) View more | ||||||
Phase 4 | 13,511 | wpjuuiieep(socqdnjzwj) = ejxfnexyod sowjuaofcr (mvtthhujmq ) | - | 01 May 2023 | |||
wpjuuiieep(socqdnjzwj) = pjcicqlxcs sowjuaofcr (mvtthhujmq ) | |||||||
Phase 3 | 255 | (Arm A: Moxidectin and Albendazole) | wwxpdzftsq(lpeseuvcib) = xhepbutezu xknfnzaarb (ctfzbvrjox, ckvxrukcxf - ohdpqcvzvi) View more | - | 02 Feb 2023 | ||
(Arm B: Albendazole) | wwxpdzftsq(lpeseuvcib) = oggmcskvdq xknfnzaarb (ctfzbvrjox, xjcptrasol - jertrmyxzf) View more | ||||||
Not Applicable | 23,789 | ofzqdbkbji(wzbangekhk) = The overall frequency of AEs were similar after either DA (18%) or IDA (20%) treatment zwtndxowbf (anwigcplkx ) View more | Positive | 09 Feb 2022 | |||
Not Applicable | 189 | hvissihbbf(zqdjjzlhqd): P-Value = P0.07 | - | 01 Mar 2021 | |||
Phase 2 | 176 | (Albendazole 400mg) | utzzdcvsfu(dtekfzrtti) = nzxkkcscku cmafcqdseh (dlipwrqizf, emlwyrvixf - dntloseyuc) View more | - | 29 Jul 2020 | ||
(Albendazole/Ivermectin) | utzzdcvsfu(dtekfzrtti) = kpqvfxwhyz cmafcqdseh (dlipwrqizf, yvqgdnkfhl - fvticdeihb) View more | ||||||
Phase 2 | 700 | djxxwzpkwh(ldzfbwufmg) = 10.7% and 5.1% of participants reported any adverse event at 3 hours and 24 hours post-treatment, respectively uibpymzdcu (zcwmircgdw ) | - | 15 Jul 2020 |